Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.
Also called NCT03219320
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose supportive care
- Phase
- Phase 2
- Enrolled
- 301 participants
- Sponsor
- Registry
-
NCT03219320
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03219320. Randomized; triple masking; primary purpose supportive care. Start 2017-06-27 (actual); primary completion 2018-11-02 (actual). Results posted on 2020-06-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Acronym
- DPN
- Condition
- Diabetic Peripheral Neuropathy
- Intervention (Drug)
- NYX-2925
- Intervention (Drug)
- Placebo
- Lead sponsor
- Aptinyx
- Collaborator
- Syneos Health
Record details
- Record id
cardio:ct-nct03219320- Content hash
f2c9ed338911f79321a32144998efceed2113ac2be23f1a678f738cf016b67d1